Potential inflammatory targets of BC
| Agent | Inflammatory pathway | Impact on tumor | Reference | |
|---|---|---|---|---|
| Metastasis | ||||
| CXCR4 | AMD3100 | SDF-1/CXCR4 | Bone metastasis | 94 |
| LIF | EC330 | LIF-CXCL1/2/3/8-CXCR2 | Migration/invasion; lung metastasis | 97 |
| CXCR2 | SB225002 | |||
| CXCR1/2 | Reparixin | IL8-CXCR1/2 | Migration/invasion | 97,85 |
| S1P | FTY720/fingolimod | SphK1/S1P/S1PR1 | Cytokines/macrophage infiltration | 100 |
| GLUT | Metformin | GM-CSF/MMP9 | Metastasis progression | 87 |
| STAT3 | Stattic | IL6-STAT3 | EMT/migration/invasion | 112 |
| Resistance to Therapy | ||||
| Autotaxin | GLPG1690 | ATX-LPA | Resistance to radiotherapy | 131 |
| CCL2 | CCL2-binding trap | CCL2-T cell | T-cell infiltration | 91 |
| Angiotensin receptor II | Telmisartan | PPARγ/NF-κB P65-IL6 | PD-L1 expression | 138 |
| Angiogenesis | ||||
| VEGF | B20-4.1.1 | VEGF | Angiogenesis | 85 |
| IL-6 | / | IL6-Treg | Reverse anti-VEGF-induced Treg recruitment | |
| ANGPTL4 | / | ANGPTL4 | Angiogenesis | 87 |
| CXCL1/2 | SCH527123 | CXCL1/8-CXCR1/2 | Angiogenesis | 72 |
| Tumorigenesis/Stemness | ||||
| pERK | PD98059 | Visfatin-pERK-CXCL1 | EMT/migration/invasion; stemness | 51 |
| COX | Aspirin | Inflammatory/angiogenic mediators | Tumorigenesis | 86 |